Academy of Managed Care Pharmacy

DarioHealth Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, November 2, 2023
Well, Nexus, Digital, Ratio, Nine Months, Operating cost, Journal of Medical Internet Research, Three Months, B2C, Medicine, Conference, Diabetes, GAAP, Acquisition, Research, Journal, Academy of Managed Care Pharmacy, Nike, Glycated hemoglobin, Type 2 diabetes, Prediabetes, Growth, Hypertension, Webcast, Marketing, The Walt Disney Company, JMIR, Aetna, Breathing, Partnership, Depreciation, Sanofi, Solera, Depression, 4836 Medon, Total, Anxiety, YTD, Video game, Food delivery, Pharmaceutical industry, Cryptocurrency, Risk management, Clothing, Property insurance, Bank, Dario

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the third quarter 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the third quarter 2023 and provided a corporate and commercial update.
  • Total operating expenses for the third quarter of 2023 were $16.2 million, compared with $16.4 million for the third quarter of 2022, and $16.1 million for the second quarter of 2023, a decrease of $0.2 million, or 1.3%, compared to the third quarter of 2022, and an increase of $62,000, or 0.4%, compared to the second quarter of 2023.
  • Total operating expenses excluding stock-based compensation, earn-out measurement, and depreciation for the third quarter of 2023 were $10.9 million, compared to $11.4 million for the third quarter of 2022, and $10.7 million for the second quarter of 2023.
  • Operating loss excluding stock-based compensation and depreciation for the third quarter of 2023 was $9.15 million compared to $8.4 million for the third quarter of 2022, and $7.5 million for the second quarter of 2023.

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Retrieved on: 
Thursday, October 26, 2023
Nexus, Patient, FDA, Academy of Managed Care Pharmacy, Research, Standard of care, Cyclophosphamide, Food, Outcomes research, ClinicoEconomics and Outcomes Research, Treatment, NS, Adrenocorticotropic hormone (medication), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, D20, QALY, Poster, Nephrotic syndrome, Congenital nephrotic syndrome, Adrenocorticotropic hormone, Sarcoidosis, Chlorambucil, Rituximab, Symphony, ICER, SOC, Calcineurin, AMCP, Azathioprine, Diagnosis, Proteinuria, Pharmaceutical industry, Medical imaging, Mallinckrodt

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health economics outcomes research on Acthar® Gel (repository corticotropin injection) for patients with advanced symptomatic sarcoidosis and nephrotic syndrome (NS)1,2 at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 in Orlando, FL October 16-19, 2023.

Key Points: 
  • Patients were monitored at the end of a three-month cycle for a partial or complete response.
  • The full data manuscript from this study was published in ClinicoEconomics and Outcomes Research on October 17, 2023.
  • "We are pleased to have shared our latest health economics research on Acthar Gel.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to Acthar.

Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Retrieved on: 
Thursday, October 19, 2023
Nexus, Markov, Pharmacy, OBR, Academy of Managed Care Pharmacy, Observation, Fungal infection, HIV, News, Acquisition, Nursing care plan, Journal, QALY, ART, Quality-adjusted life year, Database, Clinical trial, Abstract, HTE, Ibalizumab, Health, ICER, AMCP, SMR, EHR, Bronze medal, Bias, TSX, Health care, Pharmaceutical industry

The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.

Key Points: 
  • The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.
  • The analysis encompassed numerous costs, including those for treatment acquisition and administration, monitoring, adverse events, opportunistic infections, and terminal care.
  • Mortality assumptions and health-state utility values were based on disease-specific published literature and clinical trial data.
  • Over a lifetime horizon, the addition of ibalizumab to OBR increased the time patients’ HIV remained undetectable (less than 50 copies/ml) or suppressed (between 50 and 200 copies/ml).

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Retrieved on: 
Tuesday, October 17, 2023
Nexus, Food, Expo Hall, T2D, Standard of care, QALY, Risk, Hospital, Orlando World Center Marriott, Death, Mortality, AMCP, Academy of Managed Care Pharmacy, HF, FDA, ED, Heart failure, Quality-adjusted life year, National meetings of the Workers' Party of Korea, Cypress, Life imprisonment, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, SOC, Patient, Health insurance, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023, at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, Orlando, Florida.

Key Points: 
  • The budget impact was modeled as the change in medical and pharmacy costs from using sotagliflozin in addition to the standard of care (SoC) compared with the SoC alone among U.S. patients hospitalized with heart failure (HF).
  • Costs included pharmacy, inpatient, emergency department visits, and other medical and adverse event costs.
  • Amongst treated patients on sotagliflozin, commercial payers incurred increased pharmacy costs of $7,276 per patient per year as compared to patients on SoC alone.
  • Clinical outcomes of interest were hospital readmissions, emergency department (ED) visits, and all-cause deaths after an HF hospitalization.

New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes

Retrieved on: 
Tuesday, October 17, 2023
ISPOR, Type 2 diabetes, Bias, Dario Alessi, Academy of Managed Care Pharmacy, Medicaid, Digital health, HEDIS, Diabetes, Patient, Medicare, Sanofi, Research, Pharmaceutical industry, Health insurance, Dietary supplement, Nexus, Glycated hemoglobin

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research presented by Sanofi U.S. at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus ("AMCP-Nexus"), demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes.

Key Points: 
  • New data presented by Sanofi U.S. at AMCP-Nexus examined matched Dario users and non-users with type 2 diabetes to understand the impact of Dario's digital health solution.
  • A panel of independent judges awarded the research the AMCP-Nexus Gold ribbon award after assessing for relevance, originality, quality, bias and clarity.
  • "Our research collaboration with Sanofi U.S. continues to yield strong results demonstrating the real, measurable value of digital health for payers.
  • The research showed 9% more Dario users achieved HbA1c below 8% (control) compared to non-users after 12 months and 13% less Dario users stayed above 9% (poor control).

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Retrieved on: 
Wednesday, October 11, 2023
Nexus, Food, Doctor of Philosophy, Expo Hall, Risk, Hospital, MPH, Orlando World Center Marriott, SGLT2, SGLT1, AMCP, Diabetes, Academy of Managed Care Pharmacy, Heart failure, National meetings of the League of Communists of Yugoslavia, Cypress, Regulation of tobacco by the U.S. Food and Drug Administration, Health, Patient, Pharmaceutical industry, Policy

THE WOODLANDS, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting on October 16-19, 2023, in Orlando, Florida.

Key Points: 
  • Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1
    THE WOODLANDS, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting on October 16-19, 2023, in Orlando, Florida.
  • Both posters will be on display Tuesday, October 17, 2023, from 4:00 – 7:00 p.m.
  • ET during the Opening Night Reception at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, and will be included in the meeting’s first session of poster presentations on Wednesday, October 18, 2023, from 11:00 a.m. – 12:30 p.m.
  • ET in the same location.

Biologics & Biosimilars Collective Intelligence Consortium Awarded $1.4 Million Grant From the FDA

Retrieved on: 
Tuesday, October 10, 2023
Research, FDA, Biometrics, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Science, Other Science, RWD, Food, Public, Foreign, Safety, University, University of Southern Denmark, AMCP, Biopharmaceutical, Academy of Managed Care Pharmacy, University of Verona, Principal investigator, Patient, Medical device, Pharmaceutical industry, Pharmacology

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) today announced that it has been awarded a $1.4 million grant from the Food & Drug Administration (FDA) to enable biosimilar research.

Key Points: 
  • The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) today announced that it has been awarded a $1.4 million grant from the Food & Drug Administration (FDA) to enable biosimilar research.
  • The grant will support a new BBCIC study focused on identifying opportunities and challenges in using foreign real-world data (RWD) to accelerate the biosimilars approval process.
  • “The current approval process for biosimilar products is complex, delaying patients’ access to cost-effective therapies,” said Cate Lockhart, Executive Director of the BBCIC.
  • “Using real-world data from foreign countries could help improve the FDA’s work and ultimately help patients receive access to approved therapies in a timelier manner.

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

Retrieved on: 
Tuesday, May 9, 2023
Lyme disease, Prevalence, Ophthalmology, Delphi, TARS, Optometry, Science, Medicare, DB, Patient, Academy of Managed Care Pharmacy, Standard of care, PDUFA, Diagnosis, FDA, Clinical, Treatment, Disease, Pharmaceutical industry, Medical device, Demodex

IRVINE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the first quarter ended March 31, 2023, and recent business achievements.

Key Points: 
  • “We are off to a tremendous start this year highlighted by the progress and execution of our commercial strategy as we prepare for the potential launch of TP-03 in the fall,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
  • “TP-03 has the potential, if approved, to be the first FDA-approved treatment and standard of care for Demodex blepharitis, a prevalent eyelid condition that affects approximately 25 million patients in the United States.
  • We look forward to providing an update on our expected commercial launch plans during our virtual event in June.
  • In tandem, we have continued to advance our broad pipeline into proof-of-concept studies.

Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

Retrieved on: 
Thursday, March 23, 2023
Diabetes, Hospital, AMCP, Conditional sentence, UC San Diego Health, Abdominal pain, Associate, Gastroparesis, Patient, Academy of Managed Care Pharmacy, DGP, Bloating, Metoclopramide, FDA, Pharmaceutical industry, Nausea, Vomiting, Medicine

The data describes results of a study that highlights healthcare resource utilization data (HCRU) in diabetic gastroparesis patients before and after taking GIMOTI.

Key Points: 
  • The data describes results of a study that highlights healthcare resource utilization data (HCRU) in diabetic gastroparesis patients before and after taking GIMOTI.
  • HCRU is the description and quantification of patients’ total usage of healthcare services such as hospitalization or how often they visit their physician in office.
  • The cost to the healthcare system is significant and the impact on the patients and their families is considerable.
  • For decades, oral metoclopramide has been the most common and only approved treatment for patients suffering from diabetic gastroparesis.

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 21, 2023
ER, Medicaid, SG, TD, AMCP, Tardive dyskinesia, Marketing, United States Patent and Trademark Office, Prescription, Evoke, Gastroenterology, Research, Holocene, DDW, Traction, Gastroparesis, Patent, Patient, Academy of Managed Care Pharmacy, Risk, Physician, Metoclopramide, FDA, Pharmaceutical industry, Nursing, Cryptocurrency

SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments.

Key Points: 
  • “In the fourth quarter of 2022, our net product sales from prescriptions decreased slightly to $796,000, from $832,000 in the third quarter of 2022, resulting from increased prescription sales to uninsured or under-insured patients.
  • Prescription fills increased 8% in the fourth quarter 2022 compared to the third quarter while full year prescription fills increased 178%.
  • For the fourth quarter of 2022 selling, general and administrative (SG&A) expenses were approximately $2.3 million compared with $1.7 million for the fourth quarter of 2021.
  • Total operating expenses for the fourth quarter of 2022 were approximately $2.3 million compared with $1.8 million for the same period of 2021.